A new study has just been launched that will study a new drug, VIC-1911, alone or given in combination with Lumakras (sotorasib) for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), according to VITRAC Therapeutics, the maker of VIC-1911. VIC-1911 works by inhibiting the amplification or overexpression of the AURKA gene, which previous research …
The COVALENT-102 study initiated BMF-219 treatment in patients with KRAS-mutated, advanced solid tumors. The first patient with KRAS– mutated, inoperable, locally advanced or metastatic solid tumor was dosed with BMF-219, signaling the start of treatment in the phase 1/1b study COVALENT-102 (NCT05631574).1 BMF-219 is a pan-KRAS targeting inhibitor KRAS G12C, G12D, G12R and others KRAS …
Treatment with the new KRAS inhibitor begins in the phase 1/1B study, COVALENT-10 Read More »